Platelet-rich plasma: indication, limits, and clinical judgment

Platelet-rich plasma. A tool with indication, not with promise.

Platelet-rich plasma is a fraction of the patient's own blood, obtained by centrifuging it to concentrate the platelets and the growth factors they release. It is not an external medication or a biological agent of foreign origin: it comes from the same body it returns to. That has implications for both its potential and its limits, and understanding both is the starting point of any clinical conversation on the subject.

At Longevia, when a patient asks about platelet-rich plasma, the first response is not a protocol: it is an evaluation. What the evidence supports, what remains under investigation, and what simply does not apply all vary according to the application site, the clinical objective, and the patient's health conditions. All of that is reviewed before deciding whether the procedure makes sense.

How platelet-rich plasma works: what happens at the cellular level

Platelets are not simply components of coagulation. They contain granules that, when activated, release a set of signaling proteins known as growth factors. These proteins act as messengers: they instruct the cells of surrounding tissue to initiate processes of repair, proliferation, and remodeling of the extracellular matrix.

When that plasma fraction is concentrated and reintroduced into damaged tissue or tissue with limited regenerative capacity, the objective is to amplify a biological signal the body already recognizes. Nothing is introduced that the organism does not produce on its own; rather, a response that may be attenuated by age, injury, or metabolic condition is reinforced.

The quality of the platelet-rich plasma obtained depends on several factors: the patient's baseline health status, hydration level, certain medications that affect platelet function, and the processing protocol. Two people with the same diagnosis can produce a preparation with different characteristics. That is part of why the indication is not generic.

Platelet-rich plasma does not replace lost tissue. It works on tissue that still has the capacity to respond.

Areas where platelet-rich plasma has established clinical support

There are areas of use where the medical community has accumulated sufficient evidence to consider platelet-rich plasma part of a reasoned protocol. This is not evidence of absolute certainty in all contexts, but clinical consensus does exist in several of them.

Musculoskeletal injuries

Use in chronic tendinopathies, ligament injuries, and degenerative joint processes is the area with the most documented trajectory. The physiological rationale is direct: tendons and cartilage have limited vascularization, which reduces their access to the factors that normally direct tissue repair. Concentrating those factors locally responds to that anatomical limitation.

Indication in this context requires confirming that the injury is real and that no local or systemic contraindications exist. Not every tendinopathy responds the same way, and not every joint with wear is a straightforward candidate.

Androgenetic hair loss

The scalp is another tissue with accumulated support for the use of platelet-rich plasma. In androgenetic alopecia, hair follicles in the miniaturization phase may respond to growth factor stimulation, extending the active phase of the hair cycle. Results depend on the stage of loss: follicles that are already extinct cannot be recovered.

This point is clinically important because many patients arrive expecting to recover density in areas where the follicle no longer exists. The evaluation identifies which areas retain follicular activity and which do not.

Wound healing and cutaneous remodeling

In aesthetic medicine, platelet-rich plasma is used to improve texture, dermal thickness, and the healing response in chronic wounds or skin with accumulated actinic damage. Here the evidence is more heterogeneous: protocols vary, study populations vary as well, and results are not uniformly predictable. It is a valid use, but one with expectations that must be calibrated during the evaluation.

Platelet-rich plasma under investigation: what does not yet have a definitive answer

There are applications of platelet-rich plasma that generate genuine clinical interest but do not yet have sufficient evidence to be considered standard practice. Stating that clearly does not disqualify them: it means they are used in research settings or under very careful judgment, not routinely.

Use in peripheral neuropathies, spinal cord injuries, bone regeneration without combination with other biomaterials, and certain systemic inflammatory processes is being studied. The mechanisms are plausible, but clinical data are still preliminary or inconsistent across studies. At Longevia, if a patient asks about any of these indications, the response includes that distinction without ambiguity.

Telling a patient that something is under investigation is not a limitation of clinical judgment: it is part of it.

When platelet-rich plasma does not apply: contraindications that define candidacy

Platelet-rich plasma is not a procedure without contraindications. There are conditions in which applying it would represent a real risk, and that evaluation is a central part of the initial assessment.

Systemic contraindications

• Thrombocytopenia: a low platelet count means the preparation obtained will not have the minimum concentration to produce a useful biological effect, and the extraction procedure may carry additional implications.
• Active anticoagulation: certain medications alter platelet function in ways that modify both the preparation and the response of the recipient tissue. This is not an absolute contraindication in every case, but it requires medical review.
• Active hematological disorders: conditions affecting the production or function of blood cells are a direct contraindication.
• Active infection: local or systemic, an ongoing infection contraindicates the procedure. Introducing a biological preparation into infected tissue can worsen the process.
• Active neoplasms: the growth factors that PRP is intended to concentrate can interact with certain tumors. This is a contraindication that admits no exception without oncology involvement.

Local contraindications

Beyond systemic conditions, the application site itself may also contraindicate the procedure. Tissue in an acute phase of severe inflammation, a joint with an active infectious process, or an area with significant vascular damage is not a candidate without additional evaluation.

Candidacy for platelet-rich plasma is not defined by diagnosis alone: it is defined by the full picture of the patient's health condition, the application site, and the actual clinical objective.

How long platelet-rich plasma lasts: sessions, series, and follow-up

A single platelet-rich plasma procedure is rarely sufficient to produce the intended clinical effect. In general, protocols involve a series of sessions at defined intervals, followed by a follow-up period to evaluate the response.

The duration of the effect, the number of sessions, and the need for maintenance sessions vary according to the indication, the area treated, and the individual response. There is no universal protocol valid for all cases: that definition is part of the clinical plan delivered in writing after the evaluation.

What does apply generally is that follow-up is part of the protocol, not an optional step. The response to platelet-rich plasma is not always linear: there may be an initial phase of mild discomfort at the application site as the tissue processes the controlled inflammatory signal the procedure produces. That is expected and does not indicate failure.

Follow-up is not a formality: it is where we read whether the protocol is producing the intended effect.

flowchart TD
    A["Initial consultation or remote evaluation"] --> B["Review of clinical history and objectives"]
    B --> C{"Does platelet-rich plasma apply?"}
    C -->|"Yes, with clear indication"| D["Individual clinical plan in writing"]
    C -->|"Under investigation for this case"| E["Patient is informed with precision"]
    C -->|"Does not apply or contraindication exists"| F["Alternative proposed or procedure ruled out"]
    D --> G["Series of sessions per protocol"]
    G --> H["Follow-up and response evaluation"]
    H --> I["Decision on maintenance or cycle closure"]

Platelet-rich plasma in Cancún: how the process works at Longevia

Longevia is located in Puerto Cancún. Care begins with an evaluation, which can be in person or remote. That evaluation reviews the clinical history, the patient's objectives, and the conditions that determine whether platelet-rich plasma has an indication in their specific case.

If the indication exists, the plan is delivered in writing: it includes the number of sessions, the clinical objectives, and the follow-up criteria. Medical supervision accompanies the entire process, and follow-up continues when the patient returns home.

If the indication does not exist or contraindications are present, that is stated clearly along with the reasons. No standard protocols are applied without first reviewing the individual.

Signs that require emergency care, not a clinic

After any platelet-rich plasma procedure, the treated area may present mild inflammation and sensitivity. That is an expected response. There are signs, however, that require immediate emergency care and should not be handled by messaging any clinic:

• Intense, sudden, or progressive pain at the application site, especially if accompanied by pale or violet-colored skin.
• Difficulty breathing or a sensation of chest tightness.
• New neurological symptoms: loss of strength, speech disturbances, or sudden changes in vision.
• High fever with rapid onset after the procedure.

These symptoms indicate a possible complication that requires immediate emergency evaluation.

Frequently asked questions about platelet-rich plasma

Does platelet-rich plasma work for any type of joint pain?

No. The indication depends on the cause of the pain, the condition of the joint tissue, and the patient's health conditions. There are joint processes where PRP has clinical support, and others where it does not apply or where other causes must first be ruled out. That is determined during the evaluation.

How long does the effect of platelet-rich plasma last?

Duration varies according to the indication, the area treated, and the individual response. There is no single timeframe that applies to all cases. The clinical plan defines the follow-up criteria and when to consider maintenance sessions, based on each patient's progress.

Does platelet-rich plasma carry risks?

Like any procedure involving an injection, PRP carries risks: local infection, reaction at the application site, and, in infrequent cases, vascular complications. The prior evaluation and medical supervision during the procedure exist precisely to reduce those risks to the minimum possible.

Can platelet-rich plasma be combined with other regenerative treatments?

In some protocols, PRP is used in combination with other regenerative tools. Whether that applies in a particular case depends on the clinical indication and the treatment objective. Combinations are not defined generically: they are evaluated individually. For those exploring broader options, the article on how to evaluate a stem cell therapy clinic in Mexico offers useful criteria for that process.

Does platelet-rich plasma cure diseases?

No. PRP is a tool that supports tissue repair processes in specific indications. It does not cure systemic diseases or replace conventional medical treatments when those are indicated. Its use has a defined scope that is explained during the clinical evaluation.

For those who wish to review general information on medical and biological procedures, Mayo Clinic and MedlinePlus offer accessible reference material for patients.

Platelet-rich plasma is a tool with clear physiological rationale and a legitimate clinical role in certain indications. It also has real limits, contraindications that cannot be overlooked, and a set of applications that is still being studied. Knowing where the current knowledge on this procedure stands is, most likely, the most useful information anyone can have before making a decision.